Scientists from the Institute Tisch cancer at Mount Sinai developed a new approach of cancer immunotherapy by introducing immunostimulants directly into the tumor to teach the immune system to destroy the cancer throughout the body.
Vaccination in situ (directly to the tumor) has been so effective for patients with advanced lymphomas that it began testing in another trial on humans suffering from breast cancer, head and neck.
New treatment is administered a number immunostimulators in one place of the tumor. first stimulant "hires" important immune cells, dendritic cells, which play the role of "generals" of the immune army. A second stimulant activates the dendritic cells, which then instructs the T cells, "soldiers" of the immune system to kill those cancer cells. This immune army learns to recognize features of tumor cells to find and destroy them all over the body, making the tumor factory in cancer vaccines.
Scientists said that the new approach of vaccination in situ can help in many types of cancer. In addition, it can enhance the effectiveness of other immunotherapeutic agents such as inhibitors of the checkpoint.
Scientists have tested the new approach in the laboratory and in the 11 patients. Some participants complete remission was recorded, which lasted for several months or years. Laboratory studies in mice have shown that the vaccine significantly increased the success of the treatment of cancer inhibitors checkpoints.
In March, scientists have discovered a new clinical trial for patients with lymphoma, breast cancer and head and neck cancer to verify the effectiveness of the vaccine in combination with inhibitors of control points. Combination immunotherapy Since was at least three times more efficient than inhibition of the control points or separately vaccine researchers optimistic. The new approach is also tested in laboratory conditions on liver and ovarian cancer.